Loading...
AARTIPHARM logo

Aarti Pharmalabs LimitedNSEI:AARTIPHARM Stock Report

Market Cap ₹75.0b
Share Price
₹826.90
My Fair Value
₹118.16
599.8% overvalued intrinsic discount
1Y33.1%
7D0.3%
Portfolio Value
View

Aarti Pharmalabs Limited

NSEI:AARTIPHARM Stock Report

Market Cap: ₹75.0b

Aarti Pharmalabs (AARTIPHARM) Stock Overview

Manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. More details

AARTIPHARM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

AARTIPHARM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

US$5.3
70.2% undervalued intrinsic discount
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0

Aarti Pharmalabs Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aarti Pharmalabs
Historical stock prices
Current Share Price₹826.90
52 Week High₹971.00
52 Week Low₹557.05
Beta-0.54
1 Month Change-6.16%
3 Month Change-8.16%
1 Year Change33.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO186.87%

Recent News & Updates

Aarti Pharmalabs Limited (NSE:AARTIPHARM) Not Lagging Market On Growth Or Pricing

Sep 25
Aarti Pharmalabs Limited (NSE:AARTIPHARM) Not Lagging Market On Growth Or Pricing

Aarti Pharmalabs (NSE:AARTIPHARM) Has A Pretty Healthy Balance Sheet

Aug 02
Aarti Pharmalabs (NSE:AARTIPHARM) Has A Pretty Healthy Balance Sheet

Recent updates

Aarti Pharmalabs Limited (NSE:AARTIPHARM) Not Lagging Market On Growth Or Pricing

Sep 25
Aarti Pharmalabs Limited (NSE:AARTIPHARM) Not Lagging Market On Growth Or Pricing

Aarti Pharmalabs (NSE:AARTIPHARM) Has A Pretty Healthy Balance Sheet

Aug 02
Aarti Pharmalabs (NSE:AARTIPHARM) Has A Pretty Healthy Balance Sheet

If EPS Growth Is Important To You, Aarti Pharmalabs (NSE:AARTIPHARM) Presents An Opportunity

Jul 02
If EPS Growth Is Important To You, Aarti Pharmalabs (NSE:AARTIPHARM) Presents An Opportunity

Does Aarti Pharmalabs (NSE:AARTIPHARM) Deserve A Spot On Your Watchlist?

Oct 23
Does Aarti Pharmalabs (NSE:AARTIPHARM) Deserve A Spot On Your Watchlist?

Should You Be Adding Aarti Pharmalabs (NSE:AARTIPHARM) To Your Watchlist Today?

May 31
Should You Be Adding Aarti Pharmalabs (NSE:AARTIPHARM) To Your Watchlist Today?

Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Apr 19
Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)

These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well

Mar 21
These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well

Shareholder Returns

AARTIPHARMIN PharmaceuticalsIN Market
7D0.3%1.4%1.5%
1Y33.1%-7.2%-4.7%

Return vs Industry: AARTIPHARM exceeded the Indian Pharmaceuticals industry which returned -7.2% over the past year.

Return vs Market: AARTIPHARM exceeded the Indian Market which returned -4.7% over the past year.

Price Volatility

Is AARTIPHARM's price volatile compared to industry and market?
AARTIPHARM volatility
AARTIPHARM Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement5.2%
10% most volatile stocks in IN Market8.3%
10% least volatile stocks in IN Market3.2%

Stable Share Price: AARTIPHARM has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: AARTIPHARM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20192,162Hetal Galawww.aartipharmalabs.com

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects.

Aarti Pharmalabs Limited Fundamentals Summary

How do Aarti Pharmalabs's earnings and revenue compare to its market cap?
AARTIPHARM fundamental statistics
Market cap₹74.95b
Earnings (TTM)₹2.66b
Revenue (TTM)₹19.46b
28.1x
P/E Ratio
3.9x
P/S Ratio

Is AARTIPHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AARTIPHARM income statement (TTM)
Revenue₹19.46b
Cost of Revenue₹9.71b
Gross Profit₹9.75b
Other Expenses₹7.09b
Earnings₹2.66b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)29.40
Gross Margin50.11%
Net Profit Margin13.69%
Debt/Equity Ratio20.8%

How did AARTIPHARM perform over the long term?

See historical performance and comparison

Dividends

0.6%
Current Dividend Yield
17%
Payout Ratio

Does AARTIPHARM pay a reliable dividends?

See AARTIPHARM dividend history and benchmarks
When do you need to buy AARTIPHARM by to receive an upcoming dividend?
Aarti Pharmalabs dividend dates
Ex Dividend DateSep 15 2025
Dividend Pay DateOct 20 2025
Days until Ex dividend20 days
Days until Dividend pay date15 days

Does AARTIPHARM pay a reliable dividends?

See AARTIPHARM dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/04 02:28
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aarti Pharmalabs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.